<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109138">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01728064</url>
  </required_header>
  <id_info>
    <org_study_id>EPI2010-006</org_study_id>
    <nct_id>NCT01728064</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia</brief_title>
  <official_title>Safety and Efficacy Study of EPI-743 on Visual Function in Patients With Friedreich's Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edison Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edison Pharmaceuticals Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of EPI-743 on visual function and
      neurologic function in patients with Friedreich's ataxia.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual Function</measure>
    <safety_issue>No</safety_issue>
    <description>Low contrast visual acuity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Color vision</measure>
    <safety_issue>No</safety_issue>
    <description>Roth 28 hue test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurologic function</measure>
    <description>Friedreich's ataxia rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuromuscular function</measure>
    <safety_issue>No</safety_issue>
    <description>25-foot walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuromuscular function</measure>
    <safety_issue>No</safety_issue>
    <description>9-hole peg test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <safety_issue>No</safety_issue>
    <description>SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease biomarkers</measure>
    <description>Blood biomarker levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function</measure>
    <safety_issue>No</safety_issue>
    <description>Echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <safety_issue>Yes</safety_issue>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease improvement</measure>
    <description>Patient Global Improvement Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Function</measure>
    <time_frame>Baseline, Months 3, 6, 9 and 12</time_frame>
    <description>Visual field exam</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Friedreich's Ataxia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPI-743 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EPI-743 at a dose of 400 mg three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPI-743 200 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EPI-743 at a dose of 200 mg three times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-743 400 mg</intervention_name>
    <arm_group_label>EPI-743 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-743 200 mg</intervention_name>
    <arm_group_label>EPI-743 200 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of genetically confirmed Friedreich's ataxia

          2. Visual acuity at baseline more than 15 letters on EDTRS at four meters

          3. FARS score of 20 to 90

          4. Agreement to use contraception if within reproductive years (see specifics in section
             D1, page 21)

          5. Hormone replacement therapy, if used, must remain stable for the duration of the
             study

          6. Willingness and ability to comply with study procedures

          7. Willingness and ability to arrive at study site day prior to evaluations

          8. Abstention from use of dietary supplements and non-prescribed medications at least 30
             days prior to initiation of treatment and for the duration of the study. This would
             specifically include idebenone, Coenzyme Q10 and vitamin E

          9. Abstention from use of other investigative or non-approved drugs within 30 days of
             enrollment and for the duration of the study

        Exclusion Criteria:

          1. Allergy to EPI-743 or sesame oil or nuts

          2. Clinically significant bleeding condition or abnormal PT/PTT INR (INR &gt; two; PTT &gt;
             two-times normal)

          3. Liver insufficiency with LFTs greater than three-times upper normal limit at
             screening

          4. Renal insufficiency with creatinine &gt; 1.5 at screening

          5. Fat malabsorption syndromes

          6. Any other respiratory chain diseases of the mitochondria or inborn errors of
             metabolism

          7. Any other ophthalmologic conditions

          8. History of alcohol or drug abuse

          9. Clinically significant cardiomyopathy with ejection fraction &lt; 40 percent at
             screening

         10. Clinically significant arrhythmia within past two years requiring treatment

         11. Anticoagulant therapy within 30 days of enrollment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://edisonpharma.com</url>
    <description>Edison Pharmaceuticals Web Site</description>
  </link>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 4, 2013</lastchanged_date>
  <firstreceived_date>November 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Friedreich's</keyword>
  <keyword>Ataxia</keyword>
  <keyword>FRDA</keyword>
  <keyword>FA</keyword>
  <keyword>EPI-743</keyword>
  <keyword>Edison</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
